Role and regulation of Yap in KrasG12D-induced lung cancer
Metrics: PDF 850 views | HTML 1986 views | ?
Yaopan Mao1,*, Shuguo Sun1,2,* and Kenneth D. Irvine1
1Waksman Institute, Cancer Institute of New Jersey, Department of Molecular Biology and Biochemistry, Rutgers University, Piscataway, NJ 08854, USA
2Current address: Department of Anatomy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
*These authors contributed equally to this work
Kenneth D. Irvine, email: firstname.lastname@example.org
Keywords: YAP; Kras; adenocarcinoma; lung cancer
Abbreviations: Aveolar type 2: AT2; Epidermal Growth Factor Receptor: EGFR; Atypical adenomatous hyperplasia: AAH; Surfactant protein C: SpC.
Received: September 22, 2017 Accepted: November 05, 2017 Published: December 02, 2017
The Hippo pathway and its downstream transcriptional co-activator Yap influence lung cancer, but the nature of the Yap contribution has been unclear. Using a genetically engineered mouse lung cancer model, we show that Yap deletion completely blocks KrasG12D and p53 loss-driven adenocarcinoma initiation and progression, whereas heterozygosity for Yap partially suppresses lung cancer growth and progression. We also characterize Yap expression during tumor progression and find that nuclear Yap can be detected from the earliest stages of lung carcinogenesis, but at levels comparable to that in aveolar type II cells, which are a cell of origin for lung adenocarcinoma. At later stages of tumorigenesis, variations in Yap levels are detected, which correlate with differences in cell proliferation within tumors. Our observations imply that Yap is not directly activated by oncogenic Kras during lung tumorigenesis, but is nonetheless absolutely required for this tumorigenesis, and support Yap as a therapeutic target in lung adenocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.